BioSpace News Archive

Alzamend Neuro, Inc. announced that it has submitted a pre-IND meeting request for AL002 and supporting briefing documents to the Center for Biological Evaluation and Research of the U.S. Food and Drug Administration.

Lexicon Pharmaceuticals, Inc., reported financial results for the three months ended June 30, 2021 and provided an update on key milestones.

Lexicon Pharmaceuticals, Inc., announced that Craig Granowitz, M.D., Ph.D. will join the company as senior vice president and chief medical officer, effective August 2, 2021.

NuVasive, Inc., the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced that it received its latest U.S. Food and Drug Administration 510 clearance for the Pulse® platform, after receiving CE certification earlier this summer.

Cell proliferation regulation is a central part of the tissue morphogenesis process during the development of multicellular organisms.

IRADIMED CORPORATION announced financial results for the three and six months ended June 30, 2021.

ENYO Pharma, a private clinical stage biotechnology company developing innovative drug candidates, announced positive proof of concept data from Study EYP001-203 of Vonafexor in combination with pegylated-Interferon in viremic patients with chronic hepatitis B. Vonafexor met the primary endpoint of lowering HBsAg by an average of ≥ 1 log10, a key biomarker of viral activity in the liver, after 16 weeks of treatment.

Integral Molecular, the industry leader in membrane proteins, announces the launch of GeneCanvas, its proprietary protein engineering platform to optimize transgenes and other gene therapy elements.

Bristol Myers Squibb announced that the European Commission has approved Opdivo for the adjuvant treatment of adult patients with esophageal or gastroesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.

TORONTO, July 30, 2021 /PRNewswire/ - Braxia Scientific Corp., announced the filing of its fiscal fourth-quarter and year-end results for the three- and 12-month periods ending March 31, 2021.